logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs., Gedeon Report Results From 2 Phase III Trials Of Cariprazine

Forest Laboratories, Inc. (FRX) and Gedeon Richter Plc announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for treating acute exacerbation of schizophrenia.

For the primary endpoint in each study, the Positive And Negative Syndrome Scale, the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients.

Besides, all doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks.

Forest Labs noted that the results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Apple Inc. (AAPL) has scheduled its annual hardware event on Wednesday, September 7, when the tech giant is expected to unveil the most-awaited smartphone of the year-- iPhone 7. Apple has sent out invitation to the media and published the event on its website with a simple title "See you on the 7th." Although,... Starbucks Corp. (SBUX) has opened its first outlet on the island of Trinidad, as the coffee giant continues its Caribbean expansion. The new store is now open in San Fernando, Trinidad's SouthPark Entertainment Complex. Starbucks opened its first store in the Caribbean region in San Juan, Puerto... Conroe, Texas-based Country Fresh LLC., is recalling 30,000 cases of various fresh-cut vegetable products, due to a potential contamination of Listeria. The contamination was discovered during a routine sample taken at a retail store by the Georgia Department of Agriculture, which revealed the finished...
comments powered by Disqus
Follow RTT